Proceedings of the 3rd International Conference on Modern Medicine and Global Health
DOI: 10.54254/2753-8818/2025.21472

Exploring Advanced Approaches for the Isolation and Detection of Exosomes as Biomarkers for Prostate Cancer

Jiancheng Chen[1,a,*]

[1]*University College London, 26 Bedford Way, London, WC1H 0AP, United Kingdom*
a. zcemjc4@ucl.ac.uk
**corresponding author*

Abstract: The exosomes technology has emerged as a promising alternative to traditional diagnostic methods with potential advantages in detecting prostate cancer. Given the increasing incidence of prostate cancer, especially among older men, there is a strong need for non-invasive, accurate and efficient diagnostic tools. The paper aims to explore the potential of exosomes as biomarkers for prostate cancer, evaluate their application in early diagnosis and therapeutic monitoring of prostate cancer, and compare existing isolation and detection techniques. By examining recent advances in exosome isolation and detection technologies, the application of technologies such as immunocapture, nanoparticle tracking assay (NTA) and microfluidic platforms in prostate cancer detection is highlighted. Also, the detection performance of relevant biomarkers, such as prostate-specific antigen (PSA) and Survivin, in exosomes is evaluated. The results indicate that exosomes, exosomes secreted by tumor cells carry a variety of biomolecules, which can markedly boost the sensitivity and specificity of prostate cancer diagnosis when compared to the traditional PSA test. And specific exosomal biomarkers have been shown to be effective biomarkers for the early diagnosis of prostate cancer. Despite the advantages of exosome technology, several challenges remain, including the standardization of methods, the improvement of sensitivity, and the regulation of this field. It is recommended that future studies optimize separation, improve sensitivity, and develop standardized platforms to facilitate prostate cancer detection and improve patient prognosis.

Keywords: Exosomes, Extracellular Vesicles, Prostate Cancer, Biomarkers, Nanoparticle Tracking Analysis

1. Introduction

Prostate cancer is among the most prevalent malignancies in men, particularly with increased prevalence in older guys. The World Health Organization (WHO) reported that almost 1.5 million men were diagnosed with prostate cancer in 2022, ranking it among the three most prevalent malignancies worldwide, alongside lung and cervical cancers [1]. Individuals between the ages of 65 and 80 are considered to be at high risk, a designation that is closely associated with the presence of mutations in self-repair genes [2,3]. The early detection of prostate cancer is essential for enhancing treatment results. However, conventional diagnostic techniques, including ultrasound, prostate needle biopsy, and magnetic resonance imaging (MRI), are costly, intrusive, and necessitate specialist apparatus, with certain approaches possibly presenting safety hazards [4]. Consequently, identifying

DOI: 10.54254/2753-8818/2025.21472

a convenient, rapid, safe, and precise diagnostic procedure is an imperative undertaking. Recently, extracellular vesicles (EVs), particularly exosomes, have garnered interest as possible biomarkers because they transport bioactive substances such as proteins, lipids, and nucleic acids, which indicate the physiological and pathological conditions of cells. Exosomes, a distinct subtype of extracellular vesicles, facilitate intercellular communication and have significant potential for cancer diagnosis, prognosis, and treatment assessment. Current isolation and detection technologies encounter limitations concerning sensitivity, specificity, and uniformity, which restrict their clinical applicability. The paper aims to explore the viability of exosomes as biomarkers for prostate cancer, concentrating on the assessment of current isolation and detection methods while identifying the most promising strategies to enhance the utilization of exosome technology in the early diagnosis of prostate cancer. The constraints of existing methodologies and prospective avenues, particularly in enhancing detection sensitivity and specificity, are examined. The research seeks to boost exosome detection technologies to facilitate early diagnosis of prostate cancer and advance their practical application, thereby increasing treatment outcomes and patient prognosis.

2. Overview of Exosomes Technology in Prostate Cancer Detection

Exosomes are membrane-bound vesicles that are nanoscale and are released from a variety of mammalian cells, including endothelial, immunological, epithelial, mesenchymal stem, and cancer cells. Usually between 30 and 150 nm in size, exosomes are a particular subtype of EVs; their range of size is somewhat limited. Important for cell-to-cell communication, these vesicles can also reveal the physiological and pathogenic state of their cells of origin. Found in many body fluids, including blood, urine, saliva, and breast milk, exosomes span a broad spectrum of bioactive molecules, including proteins, lipids, and nucleic acids. Exosomes are interesting candidates for disease diagnosis, prognosis, and monitoring since their molecular payload offers important clues on the health and illness state of their parent cells [6]. Those released by prostate cancer cells, with distinct surface markers and biomarker profiles, have attracted significant attention for early cancer diagnosis, including prostate cancer. Tumor-derived exosomes indicate the existence and advancement of malignancy. Biomarkers like prostate-specific antigen (PSA) and Survivin, intimately associated with prostate cancer, are frequently present in exosomes and are under examination as prospective diagnostic instruments. Although PSA is extensively utilized in clinical practice for the identification of prostate cancer, its clinical efficacy is constrained by insufficient specificity and sensitivity. Increased PSA levels may arise from diseases such as benign prostatic hyperplasia (BPH) or prostatitis, resulting in false positives or negatives [10]. Exosome-based technologies possess the capability to overcome the shortcomings of conventional PSA testing by enhancing the specificity and sensitivity of prostate cancer diagnosis. Examining a wider array of biomarkers via exosome profiling might greatly enhance diagnostic precision. Advanced methods improve the detection process. These include nanoparticle tracking analysis (NTA), immunocapture ELISA, and nanoparticle flow cytometry. Studies show that exosomes from the plasma of prostate cancer patients contain significantly higher levels of survivin compared to those from healthy individuals [11]. Exosome-based technologies can improve the sensitivity and specificity of early prostate cancer diagnosis by assessing various biomarkers such as PSA and Survivin. Western blotting is frequently employed to detect exosome markers and validate their association with prostate cancer. Lysosomal-associated membrane protein 1 (LAMP1) is frequently employed to assess the purity and integrity of exosomes. These technologies provide a more sensitive and specific diagnostic approach than standard PSA testing. They offer potential advantages in early cancer detection and more precise monitoring of disease progression.

DOI: 10.54254/2753-8818/2025.21472

3. Current Research Progress and Technical Comparisons

In recent years, advancements in EV research have led to the development of various methods for their detection and characterization. The primary approaches include optical principle-based detection and immunolabeling techniques. This section will explore the practical effectiveness of these methods, with a focus on their clinical applications in EV-related studies.

3.1. Optical Principle-Based Detection

Optical principle-based detection methods primarily include NTA, flow cytometry (FCM), and surface-enhanced Raman spectroscopy (SERS). Each method for exosome detection has its advantages and limitations, with effectiveness depending on experimental conditions and sample characteristics. NTA detects exosomes by tracking their Brownian motion, using laser illumination and scattered light signals. It offers high resolution, accurately measuring exosome size and concentration. However, in high-concentration exosome samples, the accuracy of NTA may be reduced due to refraction and scattering effects. To improve accuracy, it is usually necessary to dilute the sample concentration [12]. FCM excites fluorescent markers with a laser and uses detectors (such as photodiodes) to collect scattered light signals, which are then analyzed to determine the properties of the exosomes. Although FCM allows for high-throughput detection, since the diameter of exosomes is smaller than the measurement limit of this technology, micron-level sensors are often needed. Additionally, due to the low content of exosomes in the sample, false-positive results are common, so it is necessary to dilute the sample and adjust the instrument parameters to improve the reliability of the detection [12]. SERS analyzes Raman scattering signals in the sample by exciting them with near-infrared lasers. Due to the small size of exosomes, more samples and longer analysis time are usually required to obtain a good signal-to-noise ratio when using SERS. Therefore, although SERS can provide valuable information in some cases, its sensitivity and stability are relatively low, and it still faces certain challenges.

3.2. Immunolabeling Detection

Immunolabeling detection technologies, particularly ELISA and Amplified Luminescent Proximity Homogeneous Assay (Alpha LISA), are of significant importance in exosome detection due to their high specificity, sensitivity, and quantification capabilities. Alpha LISA detects exosomes using chemiluminescence, employing microparticles labeled with photosensitive agents such as Methyl Blue (MB) and Europium (Eu). These particles emit light upon laser excitation. Unlike enzyme-linked methods, Alpha LISA avoids enzymatic background interference, improving sensitivity and accuracy, particularly for detecting exosomes at low concentrations. However, its widespread use is limited by high reagent costs and operational complexity. Besides, the stability and reproducibility of Alpha LISA require further optimization to ensure reliable results across different experimental settings [13,14]. ELISA detects target molecules using enzyme-labeled antibodies that bind specifically to antigens or antibodies immobilized on a solid-phase carrier. A color reaction is triggered upon the addition of a substrate solution. This method is widely used in exosome detection due to its high specificity and sensitivity. It provides a well-established, straightforward platform suitable for large-scale screening. The low concentration of exosomes in bodily fluids sometimes requires pre-concentration measures to improve sensitivity. Exosome heterogeneity may result in cross-reactivity, especially during multi-sample testing. Pre-treatment methods, such as immunoprecipitation and ultracentrifugation, are used to improve detection sensitivity. Despite its advantages, ELISA has limitations, including complex sample preprocessing and longer detection times. These challenges highlight the need for improvements, particularly in applications requiring rapid clinical diagnostics.

DOI: 10.54254/2753-8818/2025.21472

3.3. Novel Detection Technologies: Colorimetric Techniques and Microfluidic Systems

The combination of colorimetric techniques with microfluidic platforms has recently emerged as an innovative approach for exosome identification. These technologies not only improve detection sensitivity and efficiency but also demonstrate significant potential for clinical diagnosis in diseases like cancer. In Dr. Vaid's research, the team created a multiplexed microfluidic technology that catches exosomes using antibody-functionalized electrodes and generates surface shear forces by alternating current electrodynamic (ac EHD) fluid dynamics. This design enhances the detection sensitivity for exosomes by restricting fluid movement to the nanoscale around the electrodes [15]. Colorimetric methodologies are employed to identify exosomes on this platform. The exosome membrane undergoes a dopamine polymerization process, which is facilitated by hydrogen peroxide. This process results in the accumulation of polydopamine (PDA) and a change in the pigmentation of the solution [16]. The quantitative analysis of exosome levels through colorimetric methods is facilitated by the direct correlation between the degree of color change and exosome concentration. In comparison to conventional spot-based methods, this method enhances sensitivity by 3 to 5 orders of magnitude. As a result, it allows for highly sensitive and selective detection of exosomes associated with prostate cancer, as shown in Figure 1. This colorimetric detection method not only improves sensitivity but also makes exosome detection more convenient and efficient.



Figure 1: Colorimetric Detection of Exosomes Using the ExoAptaSensor Platform (A: (I) DA to PDA catalytic process; (II) Color change proportional to exosome concentration; (III) Absorbance at 400 nm. B: PDA deposition on exosome membrane. C: Color change over time with varying H2O2 concentrations. D: Light intensity change over time at different H2O2 levels. E: Photographs of exosome samples after color development. F: Absorbance peak at 400 nm versus exosome concentration.)

Furthermore, the advantages of this microfluidic technology reside in its capacity to selectively target exosomes from various tumor cells by modifying the sequences of the aptamers, facilitating the real-time detection of several tumor markers. It is essential for the early diagnosis, monitoring, and personalized therapy of malignancies and other disorders due to its broad clinical applicability. Nevertheless, the detection sensitivity of this method may be influenced by the generally low concentrations of exosomes in blood and urine samples, despite the substantial improvements it offers. The complexity and cost of detection may be increased as a result of interference from other components in blood samples, which may require a larger sample quantity to satisfy detection criteria. In contrast, urine is a more practical specimen, but it is still susceptible to interference from substances such as glucose and uric acid. As a result, the methodology for processing and preserving materials to ensure exosome stability is essential for improving the accuracy of detection. In order to prevent

DOI: 10.54254/2753-8818/2025.21472

sample degradation and ensure accurate results, exosome samples must be promptly managed and analyzed following collection [17,18].

4. Challenge and Future Directions

4.1. Bottlenecks and Challenges Facing Current Technologies

Exosomes have great promise for early prostate cancer and tumor diagnostics, but present methods have several difficulties. Exosome separation and purification procedures are still non-standardized. Techniques such as ultracentrifugation and immunocapture, using antibodies like CD63 and CD81, show variability in efficiency, purity, and repeatability [19]. This lack of standardization causes variation between laboratories, therefore impeding more general clinical use. Additionally, exosome extraction and analysis face technical hurdles. Microfluidic chip technology offers advantages like small sample volumes and high-throughput analysis, but its complex operation limits widespread use [19]. Existing analytical methods tend to focus on specific exosome components, such as miRNAs or proteins, lacking full-spectrum, multi-component analysis capabilities. This restricts the complete identification of tumor biomarkers. For instance, distinct miRNAs in ovarian cancer EVs have been identified as potential biomarkers for disease stages, and certain protein markers in EVs are more accurate than PSA tests in identifying prostate cancer [20]. Moreover, the potential of exosomes as a liquid biopsy tool is not fully realized, and regulatory hurdles slow their clinical implementation [21]. The underdeveloped regulatory framework for exosome isolation, analysis, and clinical application creates barriers to technological translation. Liquid biopsies, involving the separation of EVs from body fluids, offer valuable insights into tumor heterogeneity and hold promise for more comprehensive diagnostics [22].

4.2. Development and Optimization of New Technologies

Advancements in exosome detection technologies are enhancing precision and efficiency. Breakthroughs in RNA genomics, particularly next-generation sequencing (NGS), enable detailed analysis of RNA components in exosomes, aiding the discovery of novel biomarkers for prostate cancer and other tumors, as well as early diagnosis, treatment monitoring, and prognosis evaluation [19]. Microfluidic chip technology offers significant potential for exosome separation and analysis, improving throughput and sensitivity through precise fluid control [19]. This technology enhances exosome detection in clinical settings and expands its applications in liquid biopsy and personalized treatment. Additionally, the integration of machine learning and big data can improve exosome analysis by extracting deep features from clinical and experimental datasets. Machine learning algorithms can enhance accuracy and efficiency, particularly in addressing tumor heterogeneity and individual variability, overcoming the limitations of single biomarker diagnostics, and providing a more comprehensive tumor monitoring solution [19]. Several ideas have been suggested to handle present technical difficulties. Standardizing exosome separation and purification, along with optimizing techniques (e.g., ultracentrifugation, immunocapture, and affinity capture) and fostering international collaboration, can improve purity and reproducibility. Future work should concentrate on multi-component analytic methods combining RNA, protein, and lipid analysis to improve prostate cancer biomarker detection. In addition, including microfluidic chips, automated systems, and machine learning could raise sensitivity, throughput, and detection accuracy. Regulatory systems have to be simplified as exosome technologies develop to enable clinical use and for liquid biopsy to be adopted in clinical environments [19][21].

DOI: 10.54254/2753-8818/2025.21472

5. Conclusion

Providing major benefits over conventional techniques such as PSA testing, exosomes have become a viable tool for early identification and surveillance of prostate cancer. Secreted by cancer cells, these nanoscale vesicles contain specific biomarkers, including proteins, lipids, and nucleic acids, which reflect the tumor's biological characteristics and progression. Thus, they provide valuable information for early detection and ongoing monitoring of therapy. Exosome characterization has been much enhanced by techniques like NGS, immunocapture-based ELISA, and NTA, thereby facilitating the development of new prostate cancer biomarkers with considerable diagnostic power. Exosome-based diagnostics still present difficulties, nevertheless, because of the absence of consistent techniques that would guarantee sensitivity, purity, and repeatability. Sensitivity and specificity must be improved; current reliance on single biomarkers limits diagnosis possibility. Standardizing separation techniques and maximizing multi-biomarker approaches, including RNA, protein, and lipid analysis, should be the main priorities of the next studies. Dealing with these issues could transform early detection, treatment, and monitoring of prostate cancer, therefore facilitating individualized cancer care.

References

[1] *World Health Organization. (2024) Global Cancer Burden Growing, Amidst Mounting Need for Services. Saudi Med J., 45(3): 326-327.*

[2] *Bergengren, O., et al. (2023) 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review, European Urology, 84(2): 191-206.*

[3] *Rebello, R.J., et al. (2021) Prostate Cancer. Nat Rev Dis Primers, 7(1): 9.*

[4] *Schmidt, J.D. (1992) Clinical Diagnosis of Prostate Cancer. Cancer. 70(1l): 221-224.*

[5] *Abels, E.R. and Breakefield, X.O. (2016) Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake, Cell Mol Neurobiol. 36(3): 301-312.*

[6] *Choi, D.S., et al. (2013) Proteomics, transcriptomics and lipidomics of exosomes and ectosomes, Proteomics, 13: 1554-1571.*

[7] *Kim, O.Y., Lee, J. and Gho, Y.S. (2017) Extracellular vesicle mimetics: Novel alternatives to extracellular vesicle-based theranostics, drug delivery, and vaccines, Seminars in Cell & Developmental Biology, 67.*

[8] *Jang, S.C., et al. (2013) Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors, ACS Nano, 7: 7698-7710.*

[9] *Wang, W.S., Luo, J. and Wang, S.T. (2018) Recent Progress in Isolation and Detection of Extracellular Vesicles for Cancer Diagnostics, Adv. Healthcare Mater. 7: 1800484.*

[10] *Logozzi, M., et al. (2017) Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. Cancer Lett. 403 :318-329.*

[11] *Khan, S., et al. (2012) Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 7(10): e46737.*

[12] *Li, S.S., Yu, F. and Liu, W.H. (2024) Comparison of Extracellular Vesicle Characterization Methods. Chinese Journal of Biochemistry and Molecular Biology, 40(8): 1093-1101.*

[13] *Yan, L., Zhao, X.H. and Xu, Y. (2016) Advances in amplified luminescent proximity homogeneous assay linked immunosorbent assay. Chinese Bulletin of Life Sciences, 28(9): 1083-1088*

[14] *Eglen, R.M., et al. (2008) The use of alphascreen technology in HTS: current status. Curr Chem Genomics, 1: 2-10.*

[15] *Vaidyanathan, R., et al. (2014) Detecting Exosomes Specifically: A Multiplexed Device Based on Alternating Current Electrohydrodynamic Induced Nanoshearing. Anal. Chem. 2014, 86, 11125–11132.*

[16] *Bari, S.M.I., Hossain, F.B. and Nestorova, G.G. (2021) Advances in Biosensors Technology for Detection and Characterization of Extracellular Vesicles. Sensors, 21, 7645.*

[17] *Diehl, J.N., et al. (2023) A standardized method for plasma extracellular vesicle isolation and size distribution analysis. PLoS One. 18(4): e0284875*

[18] *Vitale, S.R., M. et al. (2021) Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. BMC Cancer, 21(1): 315.*

[19] *Xiong, H., et al. (2021) Recent Progress in Detection and Profiling of Cancer Cell-Derived Exosomes. Small, 17(35): e2007971.*

DOI: 10.54254/2753-8818/2025.21472

[20] *Sun, W., et al. (2018) Tumor Exosomes: A Double-Edged Sword in Cancer Therapy. Acta Pharmacol Sin. 39(4): 534-541.*

[21] *Zheng, Y., et al. (2020) Research Progress on Exosome in Malignant Tumors. Zhongguo Fei Ai Za Zhi, 23(8): 689-694.*

[22] *Bai, Y.Z. (2023) Clinical Research and Prospective Application of Extracellular Vesicles in Tumor Diagnostics. Progress in Pharmaceutical Sciences, 47(6): 433-441.*